Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Lally

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Eye (London, England)|March 25, 2023
Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trialSunil S Patel, David R Lally, Jason Hsu, et al.
Ophthalmology Science|June 17, 2024
Phase I DAVIO Trial: EYP-1901 Bioerodible, Sustained-Delivery Vorolanib Insert in Patients With Wet Age-Related Macular DegenerationSunil Patel, Philip P Storey, Mark R Barakat, et al.
Journal of Neuro-Oncology|April 22, 2025
Do the benefits of IDH mutations in high-grade glioma persist beyond the first recurrence? A multi-institutional retrospective analysisAnne R Lally, Sayak R Ghosh, Isabella L Pecorari, et al.
Journal of Neuro-Oncology|March 25, 2025
The impact of sociodemographic background on clinical presentation of high-grade gliomas: a multi-institutional retrospective analysisSayak R Ghosh, Anne R Lally, Isabella L Pecorari, et al.
Ophthalmology. Retina|May 8, 2024
Vision Loss Reduction with Avacincaptad Pegol for Geographic Atrophy: A 12-Month Post Hoc Analysis of the GATHER1 and GATHER2 TrialsCarl J Danzig, Arshad M Khanani, Peter K Kaiser, et al.
Ophthalmic Surgery, Lasers & Imaging Retina|February 17, 2025
Incomplete RPE and Outer Retinal Atrophy (iRORA) Development in Eyes With Fellow-eye Neovascular Age-related Macular DegenerationHanna Choi, Giulia Corradetti, Sophiana Lindenberg, et al.
Ophthalmology|December 17, 2025
Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 2-year efficacy and safety results from the GATHER2 phase 3 trialArshad M Khanani, Carl J Danzig, Jeffrey S Heier, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|August 12, 2009
Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyesCarol L Shields, Minoru Furuta, Archana Thangappan, et al.
Lancet (London, England)|September 11, 2023
Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trialArshad M Khanani, Sunil S Patel, Giovanni Staurenghi, et al.
Lancet (London, England)|October 21, 2023
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trialsJeffrey S Heier, Eleonora M Lad, Frank G Holz, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Eye (London, England)|March 25, 2023
Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trialSunil S Patel, David R Lally, Jason Hsu, et al.
Ophthalmology Science|June 17, 2024
Phase I DAVIO Trial: EYP-1901 Bioerodible, Sustained-Delivery Vorolanib Insert in Patients With Wet Age-Related Macular DegenerationSunil Patel, Philip P Storey, Mark R Barakat, et al.
Journal of Neuro-Oncology|April 22, 2025
Do the benefits of IDH mutations in high-grade glioma persist beyond the first recurrence? A multi-institutional retrospective analysisAnne R Lally, Sayak R Ghosh, Isabella L Pecorari, et al.
Journal of Neuro-Oncology|March 25, 2025
The impact of sociodemographic background on clinical presentation of high-grade gliomas: a multi-institutional retrospective analysisSayak R Ghosh, Anne R Lally, Isabella L Pecorari, et al.
Ophthalmology. Retina|May 8, 2024
Vision Loss Reduction with Avacincaptad Pegol for Geographic Atrophy: A 12-Month Post Hoc Analysis of the GATHER1 and GATHER2 TrialsCarl J Danzig, Arshad M Khanani, Peter K Kaiser, et al.
Ophthalmic Surgery, Lasers & Imaging Retina|February 17, 2025
Incomplete RPE and Outer Retinal Atrophy (iRORA) Development in Eyes With Fellow-eye Neovascular Age-related Macular DegenerationHanna Choi, Giulia Corradetti, Sophiana Lindenberg, et al.
Ophthalmology|December 17, 2025
Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 2-year efficacy and safety results from the GATHER2 phase 3 trialArshad M Khanani, Carl J Danzig, Jeffrey S Heier, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|August 12, 2009
Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyesCarol L Shields, Minoru Furuta, Archana Thangappan, et al.
Lancet (London, England)|September 11, 2023
Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trialArshad M Khanani, Sunil S Patel, Giovanni Staurenghi, et al.
Lancet (London, England)|October 21, 2023
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trialsJeffrey S Heier, Eleonora M Lad, Frank G Holz, et al.
Pageof 4